comparemela.com

Latest Breaking News On - Participants with deleterious germline - Page 1 : comparemela.com

Johnson & Johnson : Janssen Marks First Approval Worldwide for AKEEGA® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations

BEERSE, Belgium, 21 April 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission has granted marketing authorisation for AKEEGA®. | April 21, 2023

Beerse
Region-flamande
Belgium
Italy
Germany
France
Spain
United-kingdom
London
City-of
Japan
Janssen-cilag-gmb

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology.

Japan
United-states
San-francisco
California
American
Stevens-johnson
Bacilius-calmette-guerin
Luca-dezzani
Ania-diantonio
Hans-van-valenberg
Kiran-patel
Glaxosmithkline

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Japan
United-states
San-francisco
California
American
Stevens-johnson
Bacilius-calmette-guerin
Luca-dezzani
Ania-diantonio
Hans-van-valenberg
Kiran-patel
Glaxosmithkline

Janssen Submits Marketing Authorisation Application to EMA Seeking Approval of Niraparib and Abiraterone Acetate Dual Action Tablet Plus Prednisone for the Treatment of Patients with HRR Gene-Mutated Metastatic Castration Resistant Prostate Cancer

The submission to the European Medicines Agency is based on results from the Phase 3 MAGNITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisonefor the treatment of

Japan
United-states
American
Laura-coughlan
Gerhardt-attard
Kiran-patel
Mathai-mammen
Zejula-sm
Janssen-biotech-inc
Tesaro-inc
Janssen-research-development
Janssen-pharmaceutical-companies

vimarsana © 2020. All Rights Reserved.